TY - JOUR
T1 - Cyclosporin-induced hypertension. Incidence, pathogenesis and management
AU - Taler, Sandra J.
AU - Textor, Stephen C.
AU - Canzanello, Vincent J.
AU - Schwartz, Lora
N1 - Funding Information:
These studies were supported by National Institutes of Health General Clinical Research Grant MO1-RR-585.
PY - 1999
Y1 - 1999
N2 - Blood pressure increases soon after administration of immunosuppressive regimens using cyclosporin. Characteristic vascular changes lead to systemic and renal vasoconstriction. Changes in blood pressure are commonly associated with disturbed circadian regulation and may promote the rapid development of target organ injury, including intracranial haemorrhage, left ventricular hypertrophy and microangiopathic haemolysis. The mechanisms underlying this disorder are complex and include altered vascular endothelial function. Vasodilators such as prostacyclin and nitric oxide are suppressed, whereas vasoconstrictors, including endothelin, are increased. Changes in the kidney include vasoconstriction, reduced glomerular filtration and sodium retention. Effective therapy depends upon rigorous blood pressure control by administration of vasodilating agents, with attention to potential interactions with cyclosporin.
AB - Blood pressure increases soon after administration of immunosuppressive regimens using cyclosporin. Characteristic vascular changes lead to systemic and renal vasoconstriction. Changes in blood pressure are commonly associated with disturbed circadian regulation and may promote the rapid development of target organ injury, including intracranial haemorrhage, left ventricular hypertrophy and microangiopathic haemolysis. The mechanisms underlying this disorder are complex and include altered vascular endothelial function. Vasodilators such as prostacyclin and nitric oxide are suppressed, whereas vasoconstrictors, including endothelin, are increased. Changes in the kidney include vasoconstriction, reduced glomerular filtration and sodium retention. Effective therapy depends upon rigorous blood pressure control by administration of vasodilating agents, with attention to potential interactions with cyclosporin.
UR - http://www.scopus.com/inward/record.url?scp=0032949880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032949880&partnerID=8YFLogxK
U2 - 10.2165/00002018-199920050-00004
DO - 10.2165/00002018-199920050-00004
M3 - Review article
C2 - 10348094
AN - SCOPUS:0032949880
SN - 0114-5916
VL - 20
SP - 437
EP - 449
JO - Drug Safety
JF - Drug Safety
IS - 5
ER -